董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jakob Loven | 男 | Director | 46 | 未披露 | 未持股 | 2024-03-01 |
| Kristina Burow | 女 | Director | 50 | 未披露 | 未持股 | 2024-03-01 |
| Zachary D. Hornby | 男 | President, Chief Executive Officer and Director | 45 | 237.29万美元 | 66.98 | 2024-03-01 |
| Christine Brennan | 女 | Director | 55 | 未披露 | 未持股 | 2024-03-01 |
| Jamie Christensen | 男 | Director | 56 | 未披露 | 2.85 | 2024-03-01 |
| Fabio Pucci | 男 | Director | 39 | 未披露 | 未持股 | 2024-03-01 |
| Nancy Whiting | 女 | Director | 51 | 未披露 | 2.85 | 2024-03-01 |
| Jennifer Lew | 女 | Director | 51 | 未披露 | 2.14 | 2024-03-01 |
| Jonathan E. Lim | 男 | Chairman and Co-Founder | 52 | 未披露 | 66.93 | 2024-03-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Zachary D. Hornby | 男 | President, Chief Executive Officer and Director | 45 | 237.29万美元 | 66.98 | 2024-03-01 |
| Jami Rubin | 女 | Chief Financial Officer | 60 | 未披露 | 未持股 | 2024-03-01 |
| Klaus Wagner | 男 | Chief Medical Officer | 52 | 99.67万美元 | 7.92 | 2024-03-01 |
| Chris Hassig | 男 | Chief Scientific Officer | 52 | 90.35万美元 | 13.99 | 2024-03-01 |
| Neil Abdollahian | 男 | Chief Business Officer | 51 | 未披露 | 未持股 | 2024-03-01 |
| Jessica Oien | 女 | Chief Legal Officer and Corporate Secretary | 53 | 未披露 | 未持股 | 2024-03-01 |
董事简历
中英对照 | 中文 | 英文- Jakob Loven
-
Jakob Loven自2018年3月以来一直担任我们的董事会成员。Loven博士自2017年8月起担任投资顾问和管理公司Nextech Invest的合伙人。此前，他曾担任Third Rock Ventures公司的高级合伙人（2015年3月至2016年2月）。任职Third Rock公司期间，Loven博士曾参与创立Relay Therapeutics公司，并于2016年2月至2017年6月全职加入公司，领导战略、业务发展和运营。2013年4月至2016年7月，Loven博士还是生物制药公司SyrosPharmaceuticals，Inc.的科学联合创始人。Loven博士自2018年3月起担任上市生物制药公司Arvinas Inc.的董事会成员。Loven博士在剑桥Anglia Ruskin University获得生物医学学士学位，并在Karolinska Institutet获得医学博士学位。他在怀特海生物医学研究所（Whitehead Institute for Biomedical Research）进行博士后奖学金。
Jakob Loven,has served as a member of Boundless Bio, Inc. board of directors since April 2021. Dr. Loven joined Nextech Invest in 2017 and is currently a Managing Partner focused on precision oncology investments. Previously, Dr. Loven participated in the creation of Relay Therapeutics, Inc. and Syros Pharmaceuticals, Inc. and currently serves on the board of directors of A2 Biotherapeutics, Inc., Arrakis Therapeutics, IconOVir Bio, Hexagon Bio, and Flare Therapeutics Inc and serves as a board observer for IDRx. In the past, Dr. Loven has served on the board of directors for Vividion Therapeutics (acquired by Bayer) and Turning Point Therapeutics (acquired by Bristol Myers Squibb) as well as a number of public companies, including Kronos Bio, Inc., Arvinas Inc, Kinnate Biopharma Inc., and Autolus Therapeutics PLC. Dr. Loven received a B.A. in Biomedical Sciences from the Anglia Ruskin University of Cambridge and received a Ph.D. in Medical Sciences focused on oncology from Karolinska Institute and conducted his post-doctoral fellowship at the Whitehead Institute for Biomedical Research (WIBR) and Massachusetts Institute of Technology (MIT). - Jakob Loven自2018年3月以来一直担任我们的董事会成员。Loven博士自2017年8月起担任投资顾问和管理公司Nextech Invest的合伙人。此前，他曾担任Third Rock Ventures公司的高级合伙人（2015年3月至2016年2月）。任职Third Rock公司期间，Loven博士曾参与创立Relay Therapeutics公司，并于2016年2月至2017年6月全职加入公司，领导战略、业务发展和运营。2013年4月至2016年7月，Loven博士还是生物制药公司SyrosPharmaceuticals，Inc.的科学联合创始人。Loven博士自2018年3月起担任上市生物制药公司Arvinas Inc.的董事会成员。Loven博士在剑桥Anglia Ruskin University获得生物医学学士学位，并在Karolinska Institutet获得医学博士学位。他在怀特海生物医学研究所（Whitehead Institute for Biomedical Research）进行博士后奖学金。
- Jakob Loven,has served as a member of Boundless Bio, Inc. board of directors since April 2021. Dr. Loven joined Nextech Invest in 2017 and is currently a Managing Partner focused on precision oncology investments. Previously, Dr. Loven participated in the creation of Relay Therapeutics, Inc. and Syros Pharmaceuticals, Inc. and currently serves on the board of directors of A2 Biotherapeutics, Inc., Arrakis Therapeutics, IconOVir Bio, Hexagon Bio, and Flare Therapeutics Inc and serves as a board observer for IDRx. In the past, Dr. Loven has served on the board of directors for Vividion Therapeutics (acquired by Bayer) and Turning Point Therapeutics (acquired by Bristol Myers Squibb) as well as a number of public companies, including Kronos Bio, Inc., Arvinas Inc, Kinnate Biopharma Inc., and Autolus Therapeutics PLC. Dr. Loven received a B.A. in Biomedical Sciences from the Anglia Ruskin University of Cambridge and received a Ph.D. in Medical Sciences focused on oncology from Karolinska Institute and conducted his post-doctoral fellowship at the Whitehead Institute for Biomedical Research (WIBR) and Massachusetts Institute of Technology (MIT).
- Kristina Burow
-
Kristina Burow，自2020年1月起担任Neumora Therapeutics公司董事会成员。自2011年11月以来，Burow女士一直担任ARCH Venture Partners的董事总经理，该公司是一家专注于早期技术公司的风险投资公司，之前曾于2002年至2011年在ARCH担任过各种职务。Burow女士是私营生物技术公司Orbital Therapeutics的联合创始人，自2022年4月起担任该公司董事会成员。她目前担任多家私营生物技术公司的董事会成员，包括自2018年2月起的Boundless Bio和自2017年2月起的Autobahn Therapeutics，以及多家上市生物技术公司的董事会成员，包括自2017年6月起的Beam Therapeutics和自2014年起的Scholar Rock。她曾是被Celgene收购的上市生物技术公司Receptos, Inc.的联合创始人和董事会成员，以及私营能源公司Sapphire Energy的联合创始人和董事会成员。Burow女士曾担任多家公共生物技术和生物制药公司的董事会成员，包括2018年1月至2023年9月的Gossamer Bio、2013年至2022年3月的UNITY Biotechnology，Inc.、2015年5月至2022年2月的Metacrine、2015年至2019年12月的Sienna Biopharmaceuticals，以及2017年1月至2020年9月的Vir Biotechnology，以及多家私营生物技术和生物制药公司，包括2017年1月至2021年10月的Vividion Therapeutics，2012年至2021年10月的AgBiome，LLC，2013年至2020年9月的BlackThorn，以及2009年至2020年的Lycera。在加入ARCH之前，Burow女士是诺华生物风险基金的合伙人，也是诺华研究基金会基因组学研究所的早期雇员，这两家机构都隶属于上市制药公司诺华。Burow女士拥有加州大学伯克利分校的化学学士学位、哥伦比亚大学的化学硕士学位和芝加哥大学布斯商学院的工商管理硕士学位。
Kristina Burow,has served as a member of Boundless Bio, Inc. board of directors since June 2019. Ms. Burow has served as a Managing Director of ARCH Venture Partners, a venture capital firm, since November 2011 and previously held positions of increasing responsibility at ARCH from August 2002 to November 2011. Ms. Burow currently serves on the board of directors of several biopharmaceutical and biotechnology companies, including: Beam Therapeutics Inc., a publicly traded biotechnology company; Scholar Rock Holding Corporation, a publicly traded biopharmaceutical company; Autobahn Therapeutics, Inc., a privately held biopharmaceutical company; ROME Therapeutics, Inc., a privately held biopharmaceutical company; Asteroid Therapeutics, Inc., a privately held biopharmaceutical company; Metsera Therapeutics, Inc., a privately held biopharmaceutical company; Treeline Therapeutics Inc., a privately held biopharmaceutical company; and Pretzel Therapeutics, Inc., a privately held biopharmaceutical company. Ms. Burow is a co-founder and director of Neumora Therapeutics, Inc., a publicly traded biopharmaceutical company and Orbital Therapeutics Inc., a privately held biotechnology company. Ms. Burow previously was a co-founder and member of the board of directors of Receptos Inc., a publicly traded pharmaceutical company, until its acquisition by Celgene Corporation, a global biopharmaceutical company, and of Sapphire Energy, Inc., an energy company. Ms. Burow previously served as a member of the board of directors of Boragen, Inc., a privately held biotechnology company; Gossamer Bio, Inc., a publicly traded biopharmaceutical company; Unity Biotechnology, Inc., a publicly traded biopharmaceutical company; AgBiome Inc., a privately held biotechnology company; Metacrine, Inc., a publicly traded pharmaceutical company; Vir Biotechnology Inc., a publicly traded biotechnology company; BlackThorn Therapeutics, Inc., a privately held biopharmaceutical company; Sienna Biopharmaceuticals, Inc.; a publicly traded biopharmaceutical company; and Epirium Bio, a privately held pharmaceutical company. Ms. Burow has participated in a number of other ARCH portfolio companies including: Erasca, Inc.; Dewpoint Therapeutics, Inc.; Aledade, Inc.; Kythera Biopharmaceuticals, Inc.; Mindstrong Inc.; Kura Oncology, Inc.; and Ikaria, Inc., acquired by Madison Dearborn Partners, a private equity firm. Prior to joining ARCH, Ms. Burow served as an associate with the Novartis BioVenture Fund and was an early employee at the Genomics Institute of the Novartis Research Foundation. Ms. Burow received a B.S. in Chemistry from the University of California, Berkeley, an M.A. in Chemistry from Columbia University, and an M.B.A. from the University of Chicago. Ms. Burow's extensive experience serving on the board of directors of clinical-stage biotechnology companies and her investment experience in the life sciences industry contributed to Boundless Bio, Inc. board of directors' conclusion that she should serve as a director of Boundless Bio, Inc. - Kristina Burow，自2020年1月起担任Neumora Therapeutics公司董事会成员。自2011年11月以来，Burow女士一直担任ARCH Venture Partners的董事总经理，该公司是一家专注于早期技术公司的风险投资公司，之前曾于2002年至2011年在ARCH担任过各种职务。Burow女士是私营生物技术公司Orbital Therapeutics的联合创始人，自2022年4月起担任该公司董事会成员。她目前担任多家私营生物技术公司的董事会成员，包括自2018年2月起的Boundless Bio和自2017年2月起的Autobahn Therapeutics，以及多家上市生物技术公司的董事会成员，包括自2017年6月起的Beam Therapeutics和自2014年起的Scholar Rock。她曾是被Celgene收购的上市生物技术公司Receptos, Inc.的联合创始人和董事会成员，以及私营能源公司Sapphire Energy的联合创始人和董事会成员。Burow女士曾担任多家公共生物技术和生物制药公司的董事会成员，包括2018年1月至2023年9月的Gossamer Bio、2013年至2022年3月的UNITY Biotechnology，Inc.、2015年5月至2022年2月的Metacrine、2015年至2019年12月的Sienna Biopharmaceuticals，以及2017年1月至2020年9月的Vir Biotechnology，以及多家私营生物技术和生物制药公司，包括2017年1月至2021年10月的Vividion Therapeutics，2012年至2021年10月的AgBiome，LLC，2013年至2020年9月的BlackThorn，以及2009年至2020年的Lycera。在加入ARCH之前，Burow女士是诺华生物风险基金的合伙人，也是诺华研究基金会基因组学研究所的早期雇员，这两家机构都隶属于上市制药公司诺华。Burow女士拥有加州大学伯克利分校的化学学士学位、哥伦比亚大学的化学硕士学位和芝加哥大学布斯商学院的工商管理硕士学位。
- Kristina Burow,has served as a member of Boundless Bio, Inc. board of directors since June 2019. Ms. Burow has served as a Managing Director of ARCH Venture Partners, a venture capital firm, since November 2011 and previously held positions of increasing responsibility at ARCH from August 2002 to November 2011. Ms. Burow currently serves on the board of directors of several biopharmaceutical and biotechnology companies, including: Beam Therapeutics Inc., a publicly traded biotechnology company; Scholar Rock Holding Corporation, a publicly traded biopharmaceutical company; Autobahn Therapeutics, Inc., a privately held biopharmaceutical company; ROME Therapeutics, Inc., a privately held biopharmaceutical company; Asteroid Therapeutics, Inc., a privately held biopharmaceutical company; Metsera Therapeutics, Inc., a privately held biopharmaceutical company; Treeline Therapeutics Inc., a privately held biopharmaceutical company; and Pretzel Therapeutics, Inc., a privately held biopharmaceutical company. Ms. Burow is a co-founder and director of Neumora Therapeutics, Inc., a publicly traded biopharmaceutical company and Orbital Therapeutics Inc., a privately held biotechnology company. Ms. Burow previously was a co-founder and member of the board of directors of Receptos Inc., a publicly traded pharmaceutical company, until its acquisition by Celgene Corporation, a global biopharmaceutical company, and of Sapphire Energy, Inc., an energy company. Ms. Burow previously served as a member of the board of directors of Boragen, Inc., a privately held biotechnology company; Gossamer Bio, Inc., a publicly traded biopharmaceutical company; Unity Biotechnology, Inc., a publicly traded biopharmaceutical company; AgBiome Inc., a privately held biotechnology company; Metacrine, Inc., a publicly traded pharmaceutical company; Vir Biotechnology Inc., a publicly traded biotechnology company; BlackThorn Therapeutics, Inc., a privately held biopharmaceutical company; Sienna Biopharmaceuticals, Inc.; a publicly traded biopharmaceutical company; and Epirium Bio, a privately held pharmaceutical company. Ms. Burow has participated in a number of other ARCH portfolio companies including: Erasca, Inc.; Dewpoint Therapeutics, Inc.; Aledade, Inc.; Kythera Biopharmaceuticals, Inc.; Mindstrong Inc.; Kura Oncology, Inc.; and Ikaria, Inc., acquired by Madison Dearborn Partners, a private equity firm. Prior to joining ARCH, Ms. Burow served as an associate with the Novartis BioVenture Fund and was an early employee at the Genomics Institute of the Novartis Research Foundation. Ms. Burow received a B.S. in Chemistry from the University of California, Berkeley, an M.A. in Chemistry from Columbia University, and an M.B.A. from the University of Chicago. Ms. Burow's extensive experience serving on the board of directors of clinical-stage biotechnology companies and her investment experience in the life sciences industry contributed to Boundless Bio, Inc. board of directors' conclusion that she should serve as a director of Boundless Bio, Inc.
- Zachary D. Hornby
-
Zachary D. Hornby，自2019年5月起担任Boundless Bio，Inc.总裁、首席执行官，并担任Boundless Bio，Inc.董事会成员。此前，Hornby先生曾在上市的精准肿瘤学公司Ignyta, Inc.（已被罗氏/基因泰克收购）担任多个高管职务，包括2014年6月至2018年7月担任该公司的首席运营官，在此之前于2013年7月至2014年5月担任首席财务官，并于2012年8月至2013年7月担任企业发展副总裁。在这些职位上，Hornby先生领导了负责entrectinib（RozlytrekTM）开发的运营团队，以及最终导致罗氏于2018年2月收购的努力。在加入Ignyta之前，Hornby先生曾在Fate Therapeutics（一家专注于肿瘤学和免疫学的细胞免疫治疗公司）担任业务发展高级总监，并在奥洛兹美医疗，Inc.担任各种业务和企业发展职务。Hornby先生曾在神经分泌生物科学和L.E.K.咨询公司担任更早的新产品规划、营销和战略方面的职务。此外，Hornby先生还担任Novome Biotechnologies，Inc.、Aardvark Therapeutics，Inc.和Radionetics Oncology，Inc.的董事会成员。Hornby先生在斯坦福大学获得生物学学士学位和生物学硕士学位，并在哈佛商学院获得MBA学位。Hornby先生对Boundless Bio，Inc.业务的了解、他在企业战略和财务方面的背景，以及他在多家生物制药公司的丰富执行经验，促成了Boundless Bio，Inc.董事会的结论，即他应担任Boundless Bio，Inc.的董事。
Zachary D. Hornby,has served as Boundless Bio, Inc. President, Chief Executive Officer, and as a member of Boundless Bio, Inc. board of directors since May 2019. Previously, Mr. Hornby served in several executive positions at Ignyta, Inc. (acquired by Roche/Genentech), a publicly traded precision oncology company, including as its Chief Operating Officer from June 2014 to July 2018 and prior to that as its Chief Financial Officer from July 2013 to May 2014 and Vice President of Corporate Development from August 2012 to July 2013. In these roles, Mr. Hornby led the operational team responsible for the development of entrectinib (RozlytrekTM) and the efforts ultimately leading to the acquisition by Roche in February 2018. Prior to Ignyta, Mr. Hornby served as Senior Director of Business Development at Fate Therapeutics, a cellular immunotherapy company focused on oncology and immunology, and various business and corporate development roles at Halozyme Therapeutics, Inc.. Mr. Hornby held earlier roles in new product planning, marketing, and strategy at Neurocrine Biosciences and L.E.K. Consulting. In addition, Mr. Hornby serves as a member of the board of directors for Novome Biotechnologies, Inc., Aardvark Therapeutics, Inc., and Radionetics Oncology, Inc. Mr. Hornby received a B.S in Biology and a M.S. in Biology from Stanford University and an MBA from Harvard Business School. Mr. Hornby's knowledge of Boundless Bio, Inc. business, his background in corporate strategy and finance, and his extensive executive experience at multiple biopharmaceutical companies contributed to Boundless Bio, Inc. board of directors' conclusion that he should serve as a director of Boundless Bio, Inc. - Zachary D. Hornby，自2019年5月起担任Boundless Bio，Inc.总裁、首席执行官，并担任Boundless Bio，Inc.董事会成员。此前，Hornby先生曾在上市的精准肿瘤学公司Ignyta, Inc.（已被罗氏/基因泰克收购）担任多个高管职务，包括2014年6月至2018年7月担任该公司的首席运营官，在此之前于2013年7月至2014年5月担任首席财务官，并于2012年8月至2013年7月担任企业发展副总裁。在这些职位上，Hornby先生领导了负责entrectinib（RozlytrekTM）开发的运营团队，以及最终导致罗氏于2018年2月收购的努力。在加入Ignyta之前，Hornby先生曾在Fate Therapeutics（一家专注于肿瘤学和免疫学的细胞免疫治疗公司）担任业务发展高级总监，并在奥洛兹美医疗，Inc.担任各种业务和企业发展职务。Hornby先生曾在神经分泌生物科学和L.E.K.咨询公司担任更早的新产品规划、营销和战略方面的职务。此外，Hornby先生还担任Novome Biotechnologies，Inc.、Aardvark Therapeutics，Inc.和Radionetics Oncology，Inc.的董事会成员。Hornby先生在斯坦福大学获得生物学学士学位和生物学硕士学位，并在哈佛商学院获得MBA学位。Hornby先生对Boundless Bio，Inc.业务的了解、他在企业战略和财务方面的背景，以及他在多家生物制药公司的丰富执行经验，促成了Boundless Bio，Inc.董事会的结论，即他应担任Boundless Bio，Inc.的董事。
- Zachary D. Hornby,has served as Boundless Bio, Inc. President, Chief Executive Officer, and as a member of Boundless Bio, Inc. board of directors since May 2019. Previously, Mr. Hornby served in several executive positions at Ignyta, Inc. (acquired by Roche/Genentech), a publicly traded precision oncology company, including as its Chief Operating Officer from June 2014 to July 2018 and prior to that as its Chief Financial Officer from July 2013 to May 2014 and Vice President of Corporate Development from August 2012 to July 2013. In these roles, Mr. Hornby led the operational team responsible for the development of entrectinib (RozlytrekTM) and the efforts ultimately leading to the acquisition by Roche in February 2018. Prior to Ignyta, Mr. Hornby served as Senior Director of Business Development at Fate Therapeutics, a cellular immunotherapy company focused on oncology and immunology, and various business and corporate development roles at Halozyme Therapeutics, Inc.. Mr. Hornby held earlier roles in new product planning, marketing, and strategy at Neurocrine Biosciences and L.E.K. Consulting. In addition, Mr. Hornby serves as a member of the board of directors for Novome Biotechnologies, Inc., Aardvark Therapeutics, Inc., and Radionetics Oncology, Inc. Mr. Hornby received a B.S in Biology and a M.S. in Biology from Stanford University and an MBA from Harvard Business School. Mr. Hornby's knowledge of Boundless Bio, Inc. business, his background in corporate strategy and finance, and his extensive executive experience at multiple biopharmaceutical companies contributed to Boundless Bio, Inc. board of directors' conclusion that he should serve as a director of Boundless Bio, Inc.
- Christine Brennan
-
Christine Brennan，自2022年2月起担任Boundless Bio，Inc.董事会成员。Brennan博士自2022年起担任福泰制药 Ventures HC的董事总经理，此前曾于2017年至2021年担任MRL Ventures Fund的合伙人，并于2013年至2017年担任诺华风险基金的负责人。在她作为风险资本投资者的职业生涯中，Brennan博士曾在生物技术公司的董事会任职，包括Alector, Inc.、Entrada Therapeutics, Inc.和Altimmune, Inc.（而这些公司均为私人持股）。在加入诺华风险基金之前，布伦南博士于2010年至2013年担任Vitae制药的首席商务官，随后于2016年12月被艾尔建收购。Brennan博士获得了新罕布什尔大学的生物化学学士学位和达特茅斯医学院的神经科学博士学位，并在美国国立卫生研究院进行了发育神经生物学的博士后研究。Brennan博士在生物制药行业的丰富投资经验，以及她在众多上市公司和私营公司董事会的经验，促使Boundless Bio，Inc.董事会得出结论，她应该担任Boundless Bio，Inc.的董事。
Christine Brennan,has served as a member of Boundless Bio, Inc. board of directors since February 2022. Dr. Brennan is a Managing Director at Vertex Ventures HC since 2022 and previously Partner at MRL Ventures Fund from 2017 to 2021 and Principal at the Novartis Venture Fund from 2013 to 2017.During her career as a venture capital investor, Dr. Brennan has served on the board of directors of biotechnology companies, including Alector, Inc., Entrada Therapeutics, Inc., and Altimmune, Inc. (while the companies were privately held). Prior to the Novartis Venture Fund, Dr. Brennan was Chief Business Officer at Vitae Pharmaceuticals, from 2010 to 2013, and subsequently acquired by Allergan in December 2016. Dr. Brennan received a B.S. in Biochemistry from the University of New Hampshire and a Ph.D. in Neuroscience from Dartmouth Medical School and conducted a postdoctoral fellowship in developmental neurobiology at the National Institutes of Health. Dr. Brennan's extensive investment experience in the biopharmaceutical industry, as well as her experience on numerous public and private company boards of directors, contributed to Boundless Bio, Inc. board of directors' conclusion that she should serve as a director of Boundless Bio, Inc. - Christine Brennan，自2022年2月起担任Boundless Bio，Inc.董事会成员。Brennan博士自2022年起担任福泰制药 Ventures HC的董事总经理，此前曾于2017年至2021年担任MRL Ventures Fund的合伙人，并于2013年至2017年担任诺华风险基金的负责人。在她作为风险资本投资者的职业生涯中，Brennan博士曾在生物技术公司的董事会任职，包括Alector, Inc.、Entrada Therapeutics, Inc.和Altimmune, Inc.（而这些公司均为私人持股）。在加入诺华风险基金之前，布伦南博士于2010年至2013年担任Vitae制药的首席商务官，随后于2016年12月被艾尔建收购。Brennan博士获得了新罕布什尔大学的生物化学学士学位和达特茅斯医学院的神经科学博士学位，并在美国国立卫生研究院进行了发育神经生物学的博士后研究。Brennan博士在生物制药行业的丰富投资经验，以及她在众多上市公司和私营公司董事会的经验，促使Boundless Bio，Inc.董事会得出结论，她应该担任Boundless Bio，Inc.的董事。
- Christine Brennan,has served as a member of Boundless Bio, Inc. board of directors since February 2022. Dr. Brennan is a Managing Director at Vertex Ventures HC since 2022 and previously Partner at MRL Ventures Fund from 2017 to 2021 and Principal at the Novartis Venture Fund from 2013 to 2017.During her career as a venture capital investor, Dr. Brennan has served on the board of directors of biotechnology companies, including Alector, Inc., Entrada Therapeutics, Inc., and Altimmune, Inc. (while the companies were privately held). Prior to the Novartis Venture Fund, Dr. Brennan was Chief Business Officer at Vitae Pharmaceuticals, from 2010 to 2013, and subsequently acquired by Allergan in December 2016. Dr. Brennan received a B.S. in Biochemistry from the University of New Hampshire and a Ph.D. in Neuroscience from Dartmouth Medical School and conducted a postdoctoral fellowship in developmental neurobiology at the National Institutes of Health. Dr. Brennan's extensive investment experience in the biopharmaceutical industry, as well as her experience on numerous public and private company boards of directors, contributed to Boundless Bio, Inc. board of directors' conclusion that she should serve as a director of Boundless Bio, Inc.
- Jamie Christensen
-
Jamie Christensen，自2023年10月起担任Boundless Bio，Inc.董事会成员。Christensen博士自2014年1月起担任Mirati Therapeutics的首席科学官，该公司是一家专注于肿瘤学的生物制药公司。Mirati于2024年被百时美施贵宝（BMS）收购，现为其全资子公司。Christensen博士继续在BMS工作，负责为Mirati管道提供药物发现、转化研究、药物制造和伴随诊断研究支持。Christensen博士领导与公司临床和临床前项目的发现和推进相关的活动。在Mirati，Christensen博士曾于2014年1月至2018年12月担任高级副总裁，并于2013年6月至2014年1月担任研究副总裁。在加入Mirati之前，Christensen博士是辉瑞肿瘤精准医学负责人和肿瘤研究部门执行领导团队成员。他于2003年加入辉瑞，负责领导包括Sutent （苹果酸舒尼替尼）和Xalkori （克唑替尼）在内的项目的肿瘤学非临床研究和转化科学。在加入辉瑞之前，Christensen博士曾在Sugen Inc.（已被Pharmacia收购）任职，担任临床前研究和探索性开发的集团负责人。他在Warner Lambert/Parke-Davis的制药行业开始了他的职业生涯。克里斯滕森博士在科学期刊《Science》、《Nature》、《Cancer Cell》、《Cancer Discovery》、《New England Journal of Medicine》等杂志上撰写或合着了许多同行评审的研究文章。他在北卡罗来纳州立大学获得药理学和毒理学博士和硕士学位，在北伊利诺伊大学获得生物学学士学位。Christensen博士在生物制药行业的丰富执行和研究经验，促成了Boundless Bio，Inc.董事会关于他应担任Boundless Bio，Inc.董事的结论。
Jamie Christensen,has served as a member of Boundless Bio, Inc. board of directors since October 2023. Dr. Christensen has been the Chief Scientific Officer of Mirati Therapeutics, an oncology-focused biopharmaceutical company, since January 2014. Mirati was acquired by Bristol Myers Squibb (BMS) in 2024 and is now its wholly owned subsidiary. Dr. Christensen continues at BMS and is responsible for its drug discovery, translational research, drug manufacturing, and companion diagnostics research support for the Mirati pipeline. Dr. Christensen leads activities related to the discovery and advancement of the company's clinical and preclinical programs. At Mirati, Dr. Christensen previously served as Senior Vice President from January 2014 through December 2018,and Vice President, Research from June 2013 through January 2014. Prior to Mirati, Dr. Christensen was the Head of Oncology Precision Medicine and a member of the executive leadership team in the Oncology Research Unit at Pfizer. He joined Pfizer in 2003, where his responsibilities included leading oncology nonclinical research and translational sciences for programs including Sutent (sunitinib malate) and Xalkori (crizotinib). Prior to Pfizer, Dr. Christensen held positions at Sugen Inc. (acquired by Pharmacia), as a group leader in preclinical research and exploratory development. He began his career in the pharmaceutical industry at Warner Lambert/Parke-Davis. Dr. Christensen has authored or co-authored numerous peer-reviewed research articles in scientific journals including Science, Nature, Cancer Cell, Cancer Discovery, New England Journal of Medicine, and many others. He received his Ph.D. and M.S. in Pharmacology and Toxicology at North Carolina State University and his B.S. in Biology from Northern Illinois University. Dr. Christensen's extensive executive and research experience in the biopharmaceutical industry, contributed to Boundless Bio, Inc. board of directors' conclusion that he should serve as a director of Boundless Bio, Inc. - Jamie Christensen，自2023年10月起担任Boundless Bio，Inc.董事会成员。Christensen博士自2014年1月起担任Mirati Therapeutics的首席科学官，该公司是一家专注于肿瘤学的生物制药公司。Mirati于2024年被百时美施贵宝（BMS）收购，现为其全资子公司。Christensen博士继续在BMS工作，负责为Mirati管道提供药物发现、转化研究、药物制造和伴随诊断研究支持。Christensen博士领导与公司临床和临床前项目的发现和推进相关的活动。在Mirati，Christensen博士曾于2014年1月至2018年12月担任高级副总裁，并于2013年6月至2014年1月担任研究副总裁。在加入Mirati之前，Christensen博士是辉瑞肿瘤精准医学负责人和肿瘤研究部门执行领导团队成员。他于2003年加入辉瑞，负责领导包括Sutent （苹果酸舒尼替尼）和Xalkori （克唑替尼）在内的项目的肿瘤学非临床研究和转化科学。在加入辉瑞之前，Christensen博士曾在Sugen Inc.（已被Pharmacia收购）任职，担任临床前研究和探索性开发的集团负责人。他在Warner Lambert/Parke-Davis的制药行业开始了他的职业生涯。克里斯滕森博士在科学期刊《Science》、《Nature》、《Cancer Cell》、《Cancer Discovery》、《New England Journal of Medicine》等杂志上撰写或合着了许多同行评审的研究文章。他在北卡罗来纳州立大学获得药理学和毒理学博士和硕士学位，在北伊利诺伊大学获得生物学学士学位。Christensen博士在生物制药行业的丰富执行和研究经验，促成了Boundless Bio，Inc.董事会关于他应担任Boundless Bio，Inc.董事的结论。
- Jamie Christensen,has served as a member of Boundless Bio, Inc. board of directors since October 2023. Dr. Christensen has been the Chief Scientific Officer of Mirati Therapeutics, an oncology-focused biopharmaceutical company, since January 2014. Mirati was acquired by Bristol Myers Squibb (BMS) in 2024 and is now its wholly owned subsidiary. Dr. Christensen continues at BMS and is responsible for its drug discovery, translational research, drug manufacturing, and companion diagnostics research support for the Mirati pipeline. Dr. Christensen leads activities related to the discovery and advancement of the company's clinical and preclinical programs. At Mirati, Dr. Christensen previously served as Senior Vice President from January 2014 through December 2018,and Vice President, Research from June 2013 through January 2014. Prior to Mirati, Dr. Christensen was the Head of Oncology Precision Medicine and a member of the executive leadership team in the Oncology Research Unit at Pfizer. He joined Pfizer in 2003, where his responsibilities included leading oncology nonclinical research and translational sciences for programs including Sutent (sunitinib malate) and Xalkori (crizotinib). Prior to Pfizer, Dr. Christensen held positions at Sugen Inc. (acquired by Pharmacia), as a group leader in preclinical research and exploratory development. He began his career in the pharmaceutical industry at Warner Lambert/Parke-Davis. Dr. Christensen has authored or co-authored numerous peer-reviewed research articles in scientific journals including Science, Nature, Cancer Cell, Cancer Discovery, New England Journal of Medicine, and many others. He received his Ph.D. and M.S. in Pharmacology and Toxicology at North Carolina State University and his B.S. in Biology from Northern Illinois University. Dr. Christensen's extensive executive and research experience in the biopharmaceutical industry, contributed to Boundless Bio, Inc. board of directors' conclusion that he should serve as a director of Boundless Bio, Inc.
- Fabio Pucci
-
Fabio Pucci，自2023年4月起担任Boundless Bio，Inc.董事会成员。Pucci博士自2021年10月起担任Leaps by Bayer风险投资高级总监。Pucci博士还自2023年2月起担任Lyterian Therapeutics的董事会成员，自2022年11月起担任Mozart Therapeutics，Inc.，自2022年1月起担任Indapta Therapeutics，自2021年12月起担任Immunitas Therapeutics，所有这些公司都是私营生命科学公司。Pucci博士还自2022年7月起担任Capstan Therapeutics的董事会观察员，自2021年12月起担任Kojin Therapeutics的董事会观察员，直至2023年6月在Azitra Inc.任职。此前，Pucci博士曾于2019年10月至2021年9月在RA Capital Management，LLC担任助理/高级助理，这是一家专门从事生命科学的多阶段投资管理公司，为此他还在Hemab Therapeutics担任董事会观察员，直至2021年9月。在任职于RA资本管理公司之前，Pucci博士于2018年10月至2019年4月期间担任F-Prime Capital的MBA风险投资顾问，F-Prime Capital是一家专注于医疗保健和技术的投资集团。Pucci博士获得了爱丁堡大学细胞生物学博士学位和伦敦商学院MBA学位，并在弗朗西斯·克里克研究所进行博士后研究。Pucci博士在众多生物制药公司担任董事的经历，以及他在风险投资行业的经验，促使Boundless Bio，Inc.董事会得出结论，他应该担任Boundless Bio，Inc.的董事。
Fabio Pucci,has served as a member of Boundless Bio, Inc. board of directors since April 2023. Dr. Pucci is currently the Senior Director, Venture Investments at Leaps by Bayer since October 2021. Dr. Pucci has also served as a board member for Lyterian Therapeutics since February 2023, Mozart Therapeutics, Inc. since November 2022, Indapta Therapeutics since January 2022, and Immunitas Therapeutics since December 2021, all of which are privately held life sciences companies. Dr. Pucci has also served as a board observer for Capstan Therapeutics since July 2022, and at Kojin Therapeutics since December 2021, and until June 2023, at Azitra Inc. Previously, Dr. Pucci worked as an Associate/Senior Associate at RA Capital Management, LLC, a multi-stage investment manager specializing in life sciences, from October 2019 to September 2021, for which he also served as board observer at Hemab Therapeutics, until September 2021. Before his tenure at RA Capital Management, Dr. Pucci was an MBA Venture Capital Consultant for F-Prime Capital, an investment group specializing in healthcare and technology, from October 2018 to April 2019. Dr. Pucci has earned his Ph.D. in Cellular Biology from the University of Edinburgh and an MBA from the London Business School and conducted his postdoctoral fellowship at the Francis Crick Institute. Dr. Pucci's experience as a director of numerous biopharmaceutical companies, as well as his experience in the venture capital industry, contributed to Boundless Bio, Inc. board of directors' conclusion that he should serve as a director of Boundless Bio, Inc. - Fabio Pucci，自2023年4月起担任Boundless Bio，Inc.董事会成员。Pucci博士自2021年10月起担任Leaps by Bayer风险投资高级总监。Pucci博士还自2023年2月起担任Lyterian Therapeutics的董事会成员，自2022年11月起担任Mozart Therapeutics，Inc.，自2022年1月起担任Indapta Therapeutics，自2021年12月起担任Immunitas Therapeutics，所有这些公司都是私营生命科学公司。Pucci博士还自2022年7月起担任Capstan Therapeutics的董事会观察员，自2021年12月起担任Kojin Therapeutics的董事会观察员，直至2023年6月在Azitra Inc.任职。此前，Pucci博士曾于2019年10月至2021年9月在RA Capital Management，LLC担任助理/高级助理，这是一家专门从事生命科学的多阶段投资管理公司，为此他还在Hemab Therapeutics担任董事会观察员，直至2021年9月。在任职于RA资本管理公司之前，Pucci博士于2018年10月至2019年4月期间担任F-Prime Capital的MBA风险投资顾问，F-Prime Capital是一家专注于医疗保健和技术的投资集团。Pucci博士获得了爱丁堡大学细胞生物学博士学位和伦敦商学院MBA学位，并在弗朗西斯·克里克研究所进行博士后研究。Pucci博士在众多生物制药公司担任董事的经历，以及他在风险投资行业的经验，促使Boundless Bio，Inc.董事会得出结论，他应该担任Boundless Bio，Inc.的董事。
- Fabio Pucci,has served as a member of Boundless Bio, Inc. board of directors since April 2023. Dr. Pucci is currently the Senior Director, Venture Investments at Leaps by Bayer since October 2021. Dr. Pucci has also served as a board member for Lyterian Therapeutics since February 2023, Mozart Therapeutics, Inc. since November 2022, Indapta Therapeutics since January 2022, and Immunitas Therapeutics since December 2021, all of which are privately held life sciences companies. Dr. Pucci has also served as a board observer for Capstan Therapeutics since July 2022, and at Kojin Therapeutics since December 2021, and until June 2023, at Azitra Inc. Previously, Dr. Pucci worked as an Associate/Senior Associate at RA Capital Management, LLC, a multi-stage investment manager specializing in life sciences, from October 2019 to September 2021, for which he also served as board observer at Hemab Therapeutics, until September 2021. Before his tenure at RA Capital Management, Dr. Pucci was an MBA Venture Capital Consultant for F-Prime Capital, an investment group specializing in healthcare and technology, from October 2018 to April 2019. Dr. Pucci has earned his Ph.D. in Cellular Biology from the University of Edinburgh and an MBA from the London Business School and conducted his postdoctoral fellowship at the Francis Crick Institute. Dr. Pucci's experience as a director of numerous biopharmaceutical companies, as well as his experience in the venture capital industry, contributed to Boundless Bio, Inc. board of directors' conclusion that he should serve as a director of Boundless Bio, Inc.
- Nancy Whiting
-
Nancy Whiting，自2023年10月起担任Boundless Bio，Inc.董事会成员。自2021年9月以来，Whiting博士一直担任Recludix Pharma的首席执行官和董事会成员，Recludix Pharma是一家开发炎症性疾病和癌症新疗法的私营公司。在加入Recludix之前，Whiting博士曾在Seagen Inc.（前身为Seattle Genetics, Inc.）担任多个职位约15年（从2007年3月至2021年9月），最近担任公司战略、联盟和传播执行副总裁。在担任Seagen此职务之前，Whiting博士曾担任后期开发执行副总裁、临床开发和医疗事务高级副总裁以及实验医学负责人。在Seagen任职期间，Whiting博士在癌症药物Adcetris （brentuximab vedotin）、Padcev （enfortumab vedotin-ejfv）、Tukysa （tucatinib）和Tivdak （tisotumab vedotin）的开发和监管批准方面发挥了核心作用。在从事制药行业之前，怀廷博士在西雅图癌症护理联盟担任临床肿瘤药剂师。Whiting博士自2021年8月起担任上市生物制药公司Caribou Biosciences的董事会成员。她获得了华盛顿大学的药学博士学位和不列颠哥伦比亚大学的药学学士学位。Whiting博士在药物开发各个阶段的丰富经验，促成了Boundless Bio，Inc.董事会的结论，即她应该担任Boundless Bio，Inc.的董事。
Nancy Whiting,has served as a member of Boundless Bio, Inc. board of directors since October 2023. Since September 2021, Dr. Whiting has been the Chief Executive Officer and a member of the board of directors of Recludix Pharma, a privately held company developing novel treatments for inflammatory disease and cancer. Prior to Recludix, Dr. Whiting held various positions at Seagen Inc. (formerly Seattle Genetics, Inc.) for approximately 15 years (from March 2007 to September 2021), where she served most recently as Executive Vice President of Corporate Strategy, Alliances, and Communication. Prior to this role at Seagen, Dr. Whiting served as Executive Vice President of Late Stage Development, Senior Vice President of Clinical Development and Medical Affairs, and Head of Experimental Medicine. During her tenure at Seagen, Dr. Whiting played a central role in the development and regulatory approvals of cancer medicines Adcetris (brentuximab vedotin), Padcev (enfortumab vedotin-ejfv), Tukysa (tucatinib) and Tivdak (tisotumab vedotin). Prior to her career in the pharmaceutical industry, Dr. Whiting practiced as a clinical oncology pharmacist at the Seattle Cancer Care Alliance. Dr. Whiting has served as a member of the board of directors of Caribou Biosciences, a publicly traded biopharmaceutical company, since August 2021. She received her Pharm.D. from the University of Washington and her B.Sc. in Pharmaceutical Sciences from the University of British Columbia. Dr. Whiting's extensive experience in all phases of drug development, contributed to Boundless Bio, Inc. board of directors' conclusion that she should serve as a director of Boundless Bio, Inc. - Nancy Whiting，自2023年10月起担任Boundless Bio，Inc.董事会成员。自2021年9月以来，Whiting博士一直担任Recludix Pharma的首席执行官和董事会成员，Recludix Pharma是一家开发炎症性疾病和癌症新疗法的私营公司。在加入Recludix之前，Whiting博士曾在Seagen Inc.（前身为Seattle Genetics, Inc.）担任多个职位约15年（从2007年3月至2021年9月），最近担任公司战略、联盟和传播执行副总裁。在担任Seagen此职务之前，Whiting博士曾担任后期开发执行副总裁、临床开发和医疗事务高级副总裁以及实验医学负责人。在Seagen任职期间，Whiting博士在癌症药物Adcetris （brentuximab vedotin）、Padcev （enfortumab vedotin-ejfv）、Tukysa （tucatinib）和Tivdak （tisotumab vedotin）的开发和监管批准方面发挥了核心作用。在从事制药行业之前，怀廷博士在西雅图癌症护理联盟担任临床肿瘤药剂师。Whiting博士自2021年8月起担任上市生物制药公司Caribou Biosciences的董事会成员。她获得了华盛顿大学的药学博士学位和不列颠哥伦比亚大学的药学学士学位。Whiting博士在药物开发各个阶段的丰富经验，促成了Boundless Bio，Inc.董事会的结论，即她应该担任Boundless Bio，Inc.的董事。
- Nancy Whiting,has served as a member of Boundless Bio, Inc. board of directors since October 2023. Since September 2021, Dr. Whiting has been the Chief Executive Officer and a member of the board of directors of Recludix Pharma, a privately held company developing novel treatments for inflammatory disease and cancer. Prior to Recludix, Dr. Whiting held various positions at Seagen Inc. (formerly Seattle Genetics, Inc.) for approximately 15 years (from March 2007 to September 2021), where she served most recently as Executive Vice President of Corporate Strategy, Alliances, and Communication. Prior to this role at Seagen, Dr. Whiting served as Executive Vice President of Late Stage Development, Senior Vice President of Clinical Development and Medical Affairs, and Head of Experimental Medicine. During her tenure at Seagen, Dr. Whiting played a central role in the development and regulatory approvals of cancer medicines Adcetris (brentuximab vedotin), Padcev (enfortumab vedotin-ejfv), Tukysa (tucatinib) and Tivdak (tisotumab vedotin). Prior to her career in the pharmaceutical industry, Dr. Whiting practiced as a clinical oncology pharmacist at the Seattle Cancer Care Alliance. Dr. Whiting has served as a member of the board of directors of Caribou Biosciences, a publicly traded biopharmaceutical company, since August 2021. She received her Pharm.D. from the University of Washington and her B.Sc. in Pharmaceutical Sciences from the University of British Columbia. Dr. Whiting's extensive experience in all phases of drug development, contributed to Boundless Bio, Inc. board of directors' conclusion that she should serve as a director of Boundless Bio, Inc.
- Jennifer Lew
-
Jennifer Lew，她于2004年12月加盟Dynavax公司。她在公司担任副总裁，负责金融事务，并担任首席会计师。她曾在Dynavax公司担任高级董事和公司总会计师。在加盟本公司前，她在QRS公司任职。QRS公司是一家上市技术公司。自2002年至2004年，她在QRS公司担任总会计师助理。自2000年至2002年，她担任其董事，负责金融事务。自1994年至1999年，她在Ernst & Young公司任职，其在该公司担任的最后职务是经理。她在克莱蒙特麦肯纳学院（Claremont McKenna College）获得经济学/会计学和Government学士学位。她是一名注册会计师，如今处于非执业状态。
Jennifer Lew,has served as a member of Boundless Bio, Inc. board of directors since January 2022. Ms. Lew has been the EVP and Chief Financial Officer of Annexon Inc., a publicly traded biotechnology company, since June 2019. Prior to Annexon, she served as Chief Financial Officer and previously Senior Vice President, Finance for Aduro Biotech, which merged with Chinook Therapeutics, Inc. (a Novartis company), from 2013 to May 2019. Prior to Aduro, Ms. Lew held various finance roles at Dynavax Technologies Corp., a publicly traded biotechnology company, from 2004 to 2013, and QRS Corporation, a publicly held technology company, from 2000 to 2004. Ms. Lew began her career in the audit practice at Ernst & Young from 1994 to 1999. Ms. Lew received a B.A. in Economics/Accounting and Government from Claremont McKenna College and is a Certified Public Accountant (inactive status). Ms. Lew's background in leadership, finance, and accounting at privately held and publicly traded biotechnology companies contributed to Boundless Bio, Inc. board of directors' conclusion that she should serve as a director of Boundless Bio, Inc. - Jennifer Lew，她于2004年12月加盟Dynavax公司。她在公司担任副总裁，负责金融事务，并担任首席会计师。她曾在Dynavax公司担任高级董事和公司总会计师。在加盟本公司前，她在QRS公司任职。QRS公司是一家上市技术公司。自2002年至2004年，她在QRS公司担任总会计师助理。自2000年至2002年，她担任其董事，负责金融事务。自1994年至1999年，她在Ernst & Young公司任职，其在该公司担任的最后职务是经理。她在克莱蒙特麦肯纳学院（Claremont McKenna College）获得经济学/会计学和Government学士学位。她是一名注册会计师，如今处于非执业状态。
- Jennifer Lew,has served as a member of Boundless Bio, Inc. board of directors since January 2022. Ms. Lew has been the EVP and Chief Financial Officer of Annexon Inc., a publicly traded biotechnology company, since June 2019. Prior to Annexon, she served as Chief Financial Officer and previously Senior Vice President, Finance for Aduro Biotech, which merged with Chinook Therapeutics, Inc. (a Novartis company), from 2013 to May 2019. Prior to Aduro, Ms. Lew held various finance roles at Dynavax Technologies Corp., a publicly traded biotechnology company, from 2004 to 2013, and QRS Corporation, a publicly held technology company, from 2000 to 2004. Ms. Lew began her career in the audit practice at Ernst & Young from 1994 to 1999. Ms. Lew received a B.A. in Economics/Accounting and Government from Claremont McKenna College and is a Certified Public Accountant (inactive status). Ms. Lew's background in leadership, finance, and accounting at privately held and publicly traded biotechnology companies contributed to Boundless Bio, Inc. board of directors' conclusion that she should serve as a director of Boundless Bio, Inc.
- Jonathan E. Lim
-
Jonathan E. Lim，医学博士，Ignyta Operating的联合创始人，2011年8月成立起任主席、总裁、CEO。在2013年10月31日Ignyta Operating被Ignyta收购完成，成为其全资子公司之后，继续担任此职。加入Ignyta Operating前，他最近一职是Eclipse Therapeutics, Inc.主席和CEO，该公司是一家私营生物科技公司，开发针对癌症干细胞的单克隆抗体治疗。2011年3月，该公司由他联合创立，是 Biogen Idec的衍生公司。2012年9月出售给Bionomics Ltd.，该公司是一家澳大利亚上市生物科技公司，研究开发针对肿瘤和中枢神经系统障碍的治疗药物。他目前就任Bionomics Ltd.董事会成员。成立Eclipse Therapeutics前，2003年5月至2010年12月，他任上市生物科技公司Halozyme Therapeutics, Inc.的总裁、CEO、董事。此前，他担任过Harvard Medical School医学博士后国家研究所McKinsey & Company管理顾问，以及New York Hospital-Cornell两年外科主治医生。他拥有Stanford学士和硕士学位，McGill University医学博士学位，以及Harvard University公共卫生硕士学位。
Jonathan E. Lim,co-founded Boundless and has served as Boundless Bio, Inc. Chairman since December 2018. Dr. Lim also co-founded Erasca, Inc., a publicly traded precision oncology company, in July 2018, joined as Executive Chairman in October 2018, and has served as Chairman and Chief Executive Officer since March 2019. Dr. Lim has also served as a Venture Partner at ARCH Venture Partners since December 2018 and as Managing Partner at City Hill, LLC since founding it in 2010. Prior to co-founding each of Boundless and Erasca in 2018, Dr. Lim co-founded and served as Chairman of Ignyta, Inc., a publicly traded precision oncology company, and led it from 2012 as Chairman, Chief Executive Officer, and President through its acquisition by Roche in February 2018 and subsequent integration into Roche and Genentech in July 2018. During his tenure at Ignyta, Dr. Lim co-founded Bonti, Inc., a privately held pain management and anesthetics company, and served as its Chairman from February 2016 until its acquisition by Allergan plc in October 2018. Prior to joining Ignyta, Dr. Lim served as Chairman and Chief Executive Officer of Eclipse Therapeutics, Inc., a privately held oncology company targeting cancer stem cells that he co-founded in March 2011 as a spinout from Biogen Idec and that was sold to Bionomics Ltd. in 2012. Prior to Eclipse, Dr. Lim served as the President, Chief Executive Officer, and a Director (including as Chairman from 2004 to 2005) of Halozyme Therapeutics, Inc., a publicly traded biotechnology company, from May 2003 to December 2010. Prior to Halozyme, Dr. Lim's experience included management consulting at McKinsey & Company, a National Institutes of Health Postdoctoral Fellowship at Harvard Medical School and the Dana-Farber Cancer Institute, and two years of general surgery residency at New York Hospital-Cornell and Memorial Sloan Kettering Cancer Center. Dr. Lim has also served as a member of the board of directors of Maze Therapeutics, Inc., a private company advancing precision medicines for both rare and common diseases, since October 2019. Dr. Lim has been a member of the Board of Overseers at Scripps Research since October 2018, a member of the Board of Visitors of the Moores Cancer Center at the University of California, San Diego since 2015, and a member of the Stanford Interdisciplinary Biosciences Council since 2014. Dr. Lim has B.S. and M.S. degrees from Stanford University, an M.D. from McGill University, and an M.P.H. from Harvard University. Dr. Lim's intimate knowledge of Boundless Bio, Inc. business as a co-founder and his extensive experience as an executive officer and director of multiple public and private biotechnology companies contributed to Boundless Bio, Inc. board of directors' conclusion that he should serve as a director of Boundless Bio, Inc. - Jonathan E. Lim，医学博士，Ignyta Operating的联合创始人，2011年8月成立起任主席、总裁、CEO。在2013年10月31日Ignyta Operating被Ignyta收购完成，成为其全资子公司之后，继续担任此职。加入Ignyta Operating前，他最近一职是Eclipse Therapeutics, Inc.主席和CEO，该公司是一家私营生物科技公司，开发针对癌症干细胞的单克隆抗体治疗。2011年3月，该公司由他联合创立，是 Biogen Idec的衍生公司。2012年9月出售给Bionomics Ltd.，该公司是一家澳大利亚上市生物科技公司，研究开发针对肿瘤和中枢神经系统障碍的治疗药物。他目前就任Bionomics Ltd.董事会成员。成立Eclipse Therapeutics前，2003年5月至2010年12月，他任上市生物科技公司Halozyme Therapeutics, Inc.的总裁、CEO、董事。此前，他担任过Harvard Medical School医学博士后国家研究所McKinsey & Company管理顾问，以及New York Hospital-Cornell两年外科主治医生。他拥有Stanford学士和硕士学位，McGill University医学博士学位，以及Harvard University公共卫生硕士学位。
- Jonathan E. Lim,co-founded Boundless and has served as Boundless Bio, Inc. Chairman since December 2018. Dr. Lim also co-founded Erasca, Inc., a publicly traded precision oncology company, in July 2018, joined as Executive Chairman in October 2018, and has served as Chairman and Chief Executive Officer since March 2019. Dr. Lim has also served as a Venture Partner at ARCH Venture Partners since December 2018 and as Managing Partner at City Hill, LLC since founding it in 2010. Prior to co-founding each of Boundless and Erasca in 2018, Dr. Lim co-founded and served as Chairman of Ignyta, Inc., a publicly traded precision oncology company, and led it from 2012 as Chairman, Chief Executive Officer, and President through its acquisition by Roche in February 2018 and subsequent integration into Roche and Genentech in July 2018. During his tenure at Ignyta, Dr. Lim co-founded Bonti, Inc., a privately held pain management and anesthetics company, and served as its Chairman from February 2016 until its acquisition by Allergan plc in October 2018. Prior to joining Ignyta, Dr. Lim served as Chairman and Chief Executive Officer of Eclipse Therapeutics, Inc., a privately held oncology company targeting cancer stem cells that he co-founded in March 2011 as a spinout from Biogen Idec and that was sold to Bionomics Ltd. in 2012. Prior to Eclipse, Dr. Lim served as the President, Chief Executive Officer, and a Director (including as Chairman from 2004 to 2005) of Halozyme Therapeutics, Inc., a publicly traded biotechnology company, from May 2003 to December 2010. Prior to Halozyme, Dr. Lim's experience included management consulting at McKinsey & Company, a National Institutes of Health Postdoctoral Fellowship at Harvard Medical School and the Dana-Farber Cancer Institute, and two years of general surgery residency at New York Hospital-Cornell and Memorial Sloan Kettering Cancer Center. Dr. Lim has also served as a member of the board of directors of Maze Therapeutics, Inc., a private company advancing precision medicines for both rare and common diseases, since October 2019. Dr. Lim has been a member of the Board of Overseers at Scripps Research since October 2018, a member of the Board of Visitors of the Moores Cancer Center at the University of California, San Diego since 2015, and a member of the Stanford Interdisciplinary Biosciences Council since 2014. Dr. Lim has B.S. and M.S. degrees from Stanford University, an M.D. from McGill University, and an M.P.H. from Harvard University. Dr. Lim's intimate knowledge of Boundless Bio, Inc. business as a co-founder and his extensive experience as an executive officer and director of multiple public and private biotechnology companies contributed to Boundless Bio, Inc. board of directors' conclusion that he should serve as a director of Boundless Bio, Inc.
高管简历
中英对照 | 中文 | 英文- Zachary D. Hornby
Zachary D. Hornby，自2019年5月起担任Boundless Bio，Inc.总裁、首席执行官，并担任Boundless Bio，Inc.董事会成员。此前，Hornby先生曾在上市的精准肿瘤学公司Ignyta, Inc.（已被罗氏/基因泰克收购）担任多个高管职务，包括2014年6月至2018年7月担任该公司的首席运营官，在此之前于2013年7月至2014年5月担任首席财务官，并于2012年8月至2013年7月担任企业发展副总裁。在这些职位上，Hornby先生领导了负责entrectinib（RozlytrekTM）开发的运营团队，以及最终导致罗氏于2018年2月收购的努力。在加入Ignyta之前，Hornby先生曾在Fate Therapeutics（一家专注于肿瘤学和免疫学的细胞免疫治疗公司）担任业务发展高级总监，并在奥洛兹美医疗，Inc.担任各种业务和企业发展职务。Hornby先生曾在神经分泌生物科学和L.E.K.咨询公司担任更早的新产品规划、营销和战略方面的职务。此外，Hornby先生还担任Novome Biotechnologies，Inc.、Aardvark Therapeutics，Inc.和Radionetics Oncology，Inc.的董事会成员。Hornby先生在斯坦福大学获得生物学学士学位和生物学硕士学位，并在哈佛商学院获得MBA学位。Hornby先生对Boundless Bio，Inc.业务的了解、他在企业战略和财务方面的背景，以及他在多家生物制药公司的丰富执行经验，促成了Boundless Bio，Inc.董事会的结论，即他应担任Boundless Bio，Inc.的董事。
Zachary D. Hornby,has served as Boundless Bio, Inc. President, Chief Executive Officer, and as a member of Boundless Bio, Inc. board of directors since May 2019. Previously, Mr. Hornby served in several executive positions at Ignyta, Inc. (acquired by Roche/Genentech), a publicly traded precision oncology company, including as its Chief Operating Officer from June 2014 to July 2018 and prior to that as its Chief Financial Officer from July 2013 to May 2014 and Vice President of Corporate Development from August 2012 to July 2013. In these roles, Mr. Hornby led the operational team responsible for the development of entrectinib (RozlytrekTM) and the efforts ultimately leading to the acquisition by Roche in February 2018. Prior to Ignyta, Mr. Hornby served as Senior Director of Business Development at Fate Therapeutics, a cellular immunotherapy company focused on oncology and immunology, and various business and corporate development roles at Halozyme Therapeutics, Inc.. Mr. Hornby held earlier roles in new product planning, marketing, and strategy at Neurocrine Biosciences and L.E.K. Consulting. In addition, Mr. Hornby serves as a member of the board of directors for Novome Biotechnologies, Inc., Aardvark Therapeutics, Inc., and Radionetics Oncology, Inc. Mr. Hornby received a B.S in Biology and a M.S. in Biology from Stanford University and an MBA from Harvard Business School. Mr. Hornby's knowledge of Boundless Bio, Inc. business, his background in corporate strategy and finance, and his extensive executive experience at multiple biopharmaceutical companies contributed to Boundless Bio, Inc. board of directors' conclusion that he should serve as a director of Boundless Bio, Inc.- Zachary D. Hornby，自2019年5月起担任Boundless Bio，Inc.总裁、首席执行官，并担任Boundless Bio，Inc.董事会成员。此前，Hornby先生曾在上市的精准肿瘤学公司Ignyta, Inc.（已被罗氏/基因泰克收购）担任多个高管职务，包括2014年6月至2018年7月担任该公司的首席运营官，在此之前于2013年7月至2014年5月担任首席财务官，并于2012年8月至2013年7月担任企业发展副总裁。在这些职位上，Hornby先生领导了负责entrectinib（RozlytrekTM）开发的运营团队，以及最终导致罗氏于2018年2月收购的努力。在加入Ignyta之前，Hornby先生曾在Fate Therapeutics（一家专注于肿瘤学和免疫学的细胞免疫治疗公司）担任业务发展高级总监，并在奥洛兹美医疗，Inc.担任各种业务和企业发展职务。Hornby先生曾在神经分泌生物科学和L.E.K.咨询公司担任更早的新产品规划、营销和战略方面的职务。此外，Hornby先生还担任Novome Biotechnologies，Inc.、Aardvark Therapeutics，Inc.和Radionetics Oncology，Inc.的董事会成员。Hornby先生在斯坦福大学获得生物学学士学位和生物学硕士学位，并在哈佛商学院获得MBA学位。Hornby先生对Boundless Bio，Inc.业务的了解、他在企业战略和财务方面的背景，以及他在多家生物制药公司的丰富执行经验，促成了Boundless Bio，Inc.董事会的结论，即他应担任Boundless Bio，Inc.的董事。
- Zachary D. Hornby,has served as Boundless Bio, Inc. President, Chief Executive Officer, and as a member of Boundless Bio, Inc. board of directors since May 2019. Previously, Mr. Hornby served in several executive positions at Ignyta, Inc. (acquired by Roche/Genentech), a publicly traded precision oncology company, including as its Chief Operating Officer from June 2014 to July 2018 and prior to that as its Chief Financial Officer from July 2013 to May 2014 and Vice President of Corporate Development from August 2012 to July 2013. In these roles, Mr. Hornby led the operational team responsible for the development of entrectinib (RozlytrekTM) and the efforts ultimately leading to the acquisition by Roche in February 2018. Prior to Ignyta, Mr. Hornby served as Senior Director of Business Development at Fate Therapeutics, a cellular immunotherapy company focused on oncology and immunology, and various business and corporate development roles at Halozyme Therapeutics, Inc.. Mr. Hornby held earlier roles in new product planning, marketing, and strategy at Neurocrine Biosciences and L.E.K. Consulting. In addition, Mr. Hornby serves as a member of the board of directors for Novome Biotechnologies, Inc., Aardvark Therapeutics, Inc., and Radionetics Oncology, Inc. Mr. Hornby received a B.S in Biology and a M.S. in Biology from Stanford University and an MBA from Harvard Business School. Mr. Hornby's knowledge of Boundless Bio, Inc. business, his background in corporate strategy and finance, and his extensive executive experience at multiple biopharmaceutical companies contributed to Boundless Bio, Inc. board of directors' conclusion that he should serve as a director of Boundless Bio, Inc.
- Jami Rubin
Jami Rubin，自2023年7月起担任Boundless Bio，Inc. 首席财务官。此前，鲁宾女士于2023年5月至7月期间担任风险投资公司ARCH Venture Partners的风险合伙人，并继续兼职担任此类职务。在此之前，Rubin女士于2021年4月至2023年3月期间担任EQRx（被Revolution Medicines收购），Inc.的首席财务官，该公司是一家上市的生物技术公司。从2019年5月到2021年4月，Rubin女士在专注于咨询的全球投资银行PJT Partners担任合伙人。在此之前，鲁宾女士在医药行业担任了超过25年的股票分析师。最近，鲁宾女士于2008年9月至2018年10月担任股票研究分析师，然后是高盛 Sachs & Co. LLC的合伙人，管理全球医疗保健研究团队。此外，Rubin女士目前还担任精准医疗上市公司Relay Therapeutics, Inc.的董事会成员。鲁宾女士获得了瓦萨学院的学士学位。
Jami Rubin,has served as Boundless Bio, Inc. Chief Financial Officer since July 2023. Previously, Ms. Rubin was a venture partner in ARCH Venture Partners, a venture capital firm, from May to July 2023, and continues to serve in such role on a part-time basis. Prior to that, Ms. Rubin served as Chief Financial Officer of EQRx (acquired by Revolution Medicines), Inc., a publicly traded biotechnology company, from April 2021 to March 2023. From May 2019 to April 2021, Ms. Rubin served as a partner at PJT Partners, a global advisory-focused investment bank. Prior to that, Ms. Rubin spent more than 25 years as an equity analyst following the pharmaceutical industry. Most recently, Ms. Rubin was an equity research analyst and then partner at Goldman Sachs & Co. LLC managing the global healthcare research team from September 2008 to October 2018. In addition, Ms. Rubin currently serves as a member of the board of directors of Relay Therapeutics, Inc., a publicly traded precision medicine company. Ms. Rubin received a B.A. from Vassar College.- Jami Rubin，自2023年7月起担任Boundless Bio，Inc. 首席财务官。此前，鲁宾女士于2023年5月至7月期间担任风险投资公司ARCH Venture Partners的风险合伙人，并继续兼职担任此类职务。在此之前，Rubin女士于2021年4月至2023年3月期间担任EQRx（被Revolution Medicines收购），Inc.的首席财务官，该公司是一家上市的生物技术公司。从2019年5月到2021年4月，Rubin女士在专注于咨询的全球投资银行PJT Partners担任合伙人。在此之前，鲁宾女士在医药行业担任了超过25年的股票分析师。最近，鲁宾女士于2008年9月至2018年10月担任股票研究分析师，然后是高盛 Sachs & Co. LLC的合伙人，管理全球医疗保健研究团队。此外，Rubin女士目前还担任精准医疗上市公司Relay Therapeutics, Inc.的董事会成员。鲁宾女士获得了瓦萨学院的学士学位。
- Jami Rubin,has served as Boundless Bio, Inc. Chief Financial Officer since July 2023. Previously, Ms. Rubin was a venture partner in ARCH Venture Partners, a venture capital firm, from May to July 2023, and continues to serve in such role on a part-time basis. Prior to that, Ms. Rubin served as Chief Financial Officer of EQRx (acquired by Revolution Medicines), Inc., a publicly traded biotechnology company, from April 2021 to March 2023. From May 2019 to April 2021, Ms. Rubin served as a partner at PJT Partners, a global advisory-focused investment bank. Prior to that, Ms. Rubin spent more than 25 years as an equity analyst following the pharmaceutical industry. Most recently, Ms. Rubin was an equity research analyst and then partner at Goldman Sachs & Co. LLC managing the global healthcare research team from September 2008 to October 2018. In addition, Ms. Rubin currently serves as a member of the board of directors of Relay Therapeutics, Inc., a publicly traded precision medicine company. Ms. Rubin received a B.A. from Vassar College.
- Klaus Wagner
Klaus Wagner，自2022年2月起担任Boundless Bio，Inc.首席医疗官。在加入Boundless之前，Wagner博士曾担任Inhibrx, Inc.（被赛诺菲收购未决）的首席医疗官兼执行副总裁，这是一家上市生物制药公司，在2015年8月至2022年2月期间，他领导了从IND前到后期临床试验的多个肿瘤候选药物的开发。在加入Inhibrx之前，Wagner博士曾于2012年11月至2015年8月在邦纳 MD安德森癌症中心担任内科肿瘤学家，并在MD安德森癌症中心担任胸科、头颈内科肿瘤科的兼职助理教授。在此期间，Wagner博士作为首席研究员领导了非小细胞肺癌的多个靶向治疗和癌症免疫治疗试验。2003年10月至2006年，以及2011年9月至2012年，Wagner博士在基因泰克任职，担任过多种职务，包括科学家和诊断开发团队负责人，以及助理医疗主任；2000年11月至2003年，Wagner博士在诺华研究基金会基因组学研究所担任博士后助理。Wagner医生在圣地亚哥VA医疗中心的普通医学肿瘤诊所，以志愿者身份为患者提供每周长达5小时的肿瘤内科医生服务。Wagner博士获得了医学肿瘤学和内科的董事会认证，并在印第安纳大学医学院完成了内科培训，并在MD安德森癌症中心完成了医学肿瘤学培训。Wagner博士获得弗里德里希-亚历山大大学医学院的医学博士和博士学位。
Klaus Wagner,has served as Boundless Bio, Inc. Chief Medical Officer since February 2022. Prior to joining Boundless, Dr. Wagner served as Chief Medical Officer and Executive Vice President of Inhibrx, Inc. (acquisition by Sanofi pending), a publicly traded biopharmaceutical company, where he led the development of multiple oncology candidates from pre-IND to late-stage clinical trials from August 2015 to February 2022. Prior to Inhibrx, Dr. Wagner served as a Medical Oncologist at the Banner MD Anderson Cancer Center and as Adjunct Assistant Professor in the Department of Thoracic, Head & Neck Medical Oncology at MD Anderson Cancer Center from November 2012 to August 2015. During that time, Dr. Wagner led multiple targeted therapy and cancer immunotherapy trials in non-small cell lung cancer as a Principal Investigator. From October 2003 to 2006, and from September 2011 to 2012, Dr. Wagner was at Genentech, Inc., where he served in various roles including Scientist and Diagnostic Development Team Leader, and Assistant Medical Director; and from November 2000 to 2003, Dr. Wagner was a Post-doctoral Associate at the Genomics Institute of the Novartis Research Foundation. Dr. Wagner sees patients as a Medical Oncologist on a volunteer basis up to five hours per week in the General Medical Oncology Clinic at the VA Medical Center in San Diego. Dr. Wagner was Board-certified in Medical Oncology and Internal Medicine and completed his internal medicine training at the Indiana University School of Medicine and medical oncology training at MD Anderson Cancer Center. Dr. Wagner received an M.D. and a Ph.D. from Friedrich-Alexander University School of Medicine.- Klaus Wagner，自2022年2月起担任Boundless Bio，Inc.首席医疗官。在加入Boundless之前，Wagner博士曾担任Inhibrx, Inc.（被赛诺菲收购未决）的首席医疗官兼执行副总裁，这是一家上市生物制药公司，在2015年8月至2022年2月期间，他领导了从IND前到后期临床试验的多个肿瘤候选药物的开发。在加入Inhibrx之前，Wagner博士曾于2012年11月至2015年8月在邦纳 MD安德森癌症中心担任内科肿瘤学家，并在MD安德森癌症中心担任胸科、头颈内科肿瘤科的兼职助理教授。在此期间，Wagner博士作为首席研究员领导了非小细胞肺癌的多个靶向治疗和癌症免疫治疗试验。2003年10月至2006年，以及2011年9月至2012年，Wagner博士在基因泰克任职，担任过多种职务，包括科学家和诊断开发团队负责人，以及助理医疗主任；2000年11月至2003年，Wagner博士在诺华研究基金会基因组学研究所担任博士后助理。Wagner医生在圣地亚哥VA医疗中心的普通医学肿瘤诊所，以志愿者身份为患者提供每周长达5小时的肿瘤内科医生服务。Wagner博士获得了医学肿瘤学和内科的董事会认证，并在印第安纳大学医学院完成了内科培训，并在MD安德森癌症中心完成了医学肿瘤学培训。Wagner博士获得弗里德里希-亚历山大大学医学院的医学博士和博士学位。
- Klaus Wagner,has served as Boundless Bio, Inc. Chief Medical Officer since February 2022. Prior to joining Boundless, Dr. Wagner served as Chief Medical Officer and Executive Vice President of Inhibrx, Inc. (acquisition by Sanofi pending), a publicly traded biopharmaceutical company, where he led the development of multiple oncology candidates from pre-IND to late-stage clinical trials from August 2015 to February 2022. Prior to Inhibrx, Dr. Wagner served as a Medical Oncologist at the Banner MD Anderson Cancer Center and as Adjunct Assistant Professor in the Department of Thoracic, Head & Neck Medical Oncology at MD Anderson Cancer Center from November 2012 to August 2015. During that time, Dr. Wagner led multiple targeted therapy and cancer immunotherapy trials in non-small cell lung cancer as a Principal Investigator. From October 2003 to 2006, and from September 2011 to 2012, Dr. Wagner was at Genentech, Inc., where he served in various roles including Scientist and Diagnostic Development Team Leader, and Assistant Medical Director; and from November 2000 to 2003, Dr. Wagner was a Post-doctoral Associate at the Genomics Institute of the Novartis Research Foundation. Dr. Wagner sees patients as a Medical Oncologist on a volunteer basis up to five hours per week in the General Medical Oncology Clinic at the VA Medical Center in San Diego. Dr. Wagner was Board-certified in Medical Oncology and Internal Medicine and completed his internal medicine training at the Indiana University School of Medicine and medical oncology training at MD Anderson Cancer Center. Dr. Wagner received an M.D. and a Ph.D. from Friedrich-Alexander University School of Medicine.
- Chris Hassig
Chris Hassig，自2019年11月起担任我们的首席科学官。在加入Boundless之前，Hassig博士曾任职于Sierra Oncology, Inc.（已被葛兰素史克收购），这是一家上市的精准肿瘤学公司，曾于2016年6月至2019年11月担任各种领导职务，包括首席科学官和研究高级副总裁。在加入Sierra之前，Hassig博士曾在Sanford Burnham Prebys Medical Discovery Institute担任药物发现副总裁，在那里他领导了针对创新靶点的新型小分子疗法的发现和开发。哈西格博士还在KalyPsys，Inc.的生物学和先导发现部门担任过多个职位，这是一家专门从事小分子药物发现和开发的私营生物制药公司。哈西格博士在加州大学圣地亚哥分校获得化学和生物化学学士学位，在哈佛大学获得分子和细胞生物学博士学位，还在加州大学伯克利分校完成了博士后奖学金。
Chris Hassig,has served as Boundless Bio, Inc. Chief Scientific Officer since November 2019. Before Boundless, Dr. Hassig was with Sierra Oncology, Inc. (acquired by GlaxoSmithKline), a publicly traded precision oncology company where he served in various leadership roles including Chief Scientific Officer and Senior Vice President of Research, from June 2016 to November 2019. Prior to Sierra, Dr. Hassig served as Vice President of Drug Discovery at the Sanford Burnham Prebys Medical Discovery Institute where he led the discovery and development of novel small molecule therapeutics against innovative targets. Dr. Hassig also held several positions within the Biology and Lead Discovery departments at Kalypsys, Inc., a private biopharmaceutical company specializing in small molecule drug discovery and development. Dr. Hassig received a B.A. in Chemistry and Biochemistry from the University of California, San Diego, a Ph.D. in Molecular and Cellular Biology from Harvard University, and also completed a Postdoctoral Fellowship at the University of California, Berkeley.- Chris Hassig，自2019年11月起担任我们的首席科学官。在加入Boundless之前，Hassig博士曾任职于Sierra Oncology, Inc.（已被葛兰素史克收购），这是一家上市的精准肿瘤学公司，曾于2016年6月至2019年11月担任各种领导职务，包括首席科学官和研究高级副总裁。在加入Sierra之前，Hassig博士曾在Sanford Burnham Prebys Medical Discovery Institute担任药物发现副总裁，在那里他领导了针对创新靶点的新型小分子疗法的发现和开发。哈西格博士还在KalyPsys，Inc.的生物学和先导发现部门担任过多个职位，这是一家专门从事小分子药物发现和开发的私营生物制药公司。哈西格博士在加州大学圣地亚哥分校获得化学和生物化学学士学位，在哈佛大学获得分子和细胞生物学博士学位，还在加州大学伯克利分校完成了博士后奖学金。
- Chris Hassig,has served as Boundless Bio, Inc. Chief Scientific Officer since November 2019. Before Boundless, Dr. Hassig was with Sierra Oncology, Inc. (acquired by GlaxoSmithKline), a publicly traded precision oncology company where he served in various leadership roles including Chief Scientific Officer and Senior Vice President of Research, from June 2016 to November 2019. Prior to Sierra, Dr. Hassig served as Vice President of Drug Discovery at the Sanford Burnham Prebys Medical Discovery Institute where he led the discovery and development of novel small molecule therapeutics against innovative targets. Dr. Hassig also held several positions within the Biology and Lead Discovery departments at Kalypsys, Inc., a private biopharmaceutical company specializing in small molecule drug discovery and development. Dr. Hassig received a B.A. in Chemistry and Biochemistry from the University of California, San Diego, a Ph.D. in Molecular and Cellular Biology from Harvard University, and also completed a Postdoctoral Fellowship at the University of California, Berkeley.
- Neil Abdollahian
Neil Abdollahian，自2021年8月起担任Boundless Bio，Inc.首席商务官。在加入Boundless之前，Abdollahian先生于2016年7月至2021年8月期间担任上市生物制药公司Cidara Therapeutics, Inc.的首席商务官。在加入Cidara之前，Abdollahian先生是Clarity Point Partners，LLC的董事总经理，该公司是一家战略咨询公司，专注于企业发展计划，包括生物制药产品收购和许可。在此之前，Abdollahian先生曾担任过各种领导职务，包括在TRIUS治疗担任业务发展副总裁，在那里他领导了导致被Cubist Pharmaceuticals收购的努力。Abdollahian先生还曾在Emerging Growth Capital Pty、Avanir制药和Isis Pharmaceuticals担任过更早的各种业务和企业发展职务。Abdollahian获得了乔治华盛顿大学的生物学学士学位、新墨西哥大学医学院的生物医学科学硕士学位以及佩珀代因大学的MBA学位。
Neil Abdollahian,has served as Boundless Bio, Inc. Chief Business Officer since August 2021. Prior to Boundless, Mr. Abdollahian served as Chief Business Officer of Cidara Therapeutics, Inc., a publicly traded biopharmaceutical company, from July 2016 to August 2021. Prior to Cidara, Mr. Abdollahian was Managing Director of Clarity Point Partners, LLC, a strategic advisory firm focused on corporate development initiatives including biopharmaceutical product acquisitions and licensing. Previously, Mr. Abdollahian served in various leadership roles including Vice President of Business Development at Trius Therapeutics, Inc., where he led the efforts resulting in the acquisition by Cubist Pharmaceuticals. Mr. Abdollahian also served earlier in various business and corporate development roles at Emerging Growth Capital Pty, Avanir Pharmaceuticals, and Isis Pharmaceuticals.Mr. Abdollahian received a B.S in Biology from the George Washington University, a M.S. in Biomedical Sciences from University of New Mexico Medical School, and an MBA from Pepperdine University.- Neil Abdollahian，自2021年8月起担任Boundless Bio，Inc.首席商务官。在加入Boundless之前，Abdollahian先生于2016年7月至2021年8月期间担任上市生物制药公司Cidara Therapeutics, Inc.的首席商务官。在加入Cidara之前，Abdollahian先生是Clarity Point Partners，LLC的董事总经理，该公司是一家战略咨询公司，专注于企业发展计划，包括生物制药产品收购和许可。在此之前，Abdollahian先生曾担任过各种领导职务，包括在TRIUS治疗担任业务发展副总裁，在那里他领导了导致被Cubist Pharmaceuticals收购的努力。Abdollahian先生还曾在Emerging Growth Capital Pty、Avanir制药和Isis Pharmaceuticals担任过更早的各种业务和企业发展职务。Abdollahian获得了乔治华盛顿大学的生物学学士学位、新墨西哥大学医学院的生物医学科学硕士学位以及佩珀代因大学的MBA学位。
- Neil Abdollahian,has served as Boundless Bio, Inc. Chief Business Officer since August 2021. Prior to Boundless, Mr. Abdollahian served as Chief Business Officer of Cidara Therapeutics, Inc., a publicly traded biopharmaceutical company, from July 2016 to August 2021. Prior to Cidara, Mr. Abdollahian was Managing Director of Clarity Point Partners, LLC, a strategic advisory firm focused on corporate development initiatives including biopharmaceutical product acquisitions and licensing. Previously, Mr. Abdollahian served in various leadership roles including Vice President of Business Development at Trius Therapeutics, Inc., where he led the efforts resulting in the acquisition by Cubist Pharmaceuticals. Mr. Abdollahian also served earlier in various business and corporate development roles at Emerging Growth Capital Pty, Avanir Pharmaceuticals, and Isis Pharmaceuticals.Mr. Abdollahian received a B.S in Biology from the George Washington University, a M.S. in Biomedical Sciences from University of New Mexico Medical School, and an MBA from Pepperdine University.
- Jessica Oien
Jessica Oien自2024年1月起担任Boundless Bio，Inc.首席法务官和公司秘书，并于2021年8月至2023年12月担任Boundless Bio，Inc.总法律顾问和公司秘书。在加入Boundless之前，Oien女士于2018年9月至2021年8月期间在上市的生物制药公司Cidara Therapeutics, Inc.担任总法律顾问和公司秘书。在加入Cidara之前，Oien女士曾在上市的生物制药公司Otonomy, Inc.担任法律与合规副总裁，2015年至2018年担任商业业务的法律主管，并带头推动商业合规计划。她曾担任Pernix Therapeutics法律与合规副总裁；Somaxon Pharmaceuticals法律事务与合规副总裁；Verus Pharmaceuticals法律事务高级总监，Elan Pharmaceuticals法律事务高级总监等类似职务。Oien女士的法律生涯始于Brobeck，Phleger & Harrison LLP和Milbank，Tweed，Hadley & McCloy LLP等国家律师事务所的公司法律顾问。Oien女士获得了北达科他州立大学经济学和政治学学士学位以及洛约拉法学院法学博士学位。
Jessica Oien,has served as Boundless Bio, Inc. Chief Legal Officer and Corporate Secretary since January 2024 and as Boundless Bio, Inc. General Counsel and Corporate Secretary from August 2021 through December 2023. Prior to joining Boundless, Ms. Oien served as General Counsel and Corporate Secretary at Cidara Therapeutics, Inc., a publicly traded biopharmaceutical company, from September 2018 to August 2021. Before Cidara, Ms. Oien served as Vice President, Legal and Compliance at Otonomy, Inc., a publicly traded biopharmaceutical company, where she was the legal lead for the commercial business from 2015 to 2018 and spearheaded the commercial compliance program. She served in similar roles as Vice President, Legal and Compliance for Pernix Therapeutics; Vice President, Legal Affairs & Compliance for Somaxon Pharmaceuticals; and Senior Director, Legal Affairs for Verus Pharmaceuticals, and Senior Director, Legal Affairs at Elan Pharmaceuticals. Ms. Oien began her legal career as corporate counsel at national law firms including Brobeck, Phleger & Harrison LLP and Milbank, Tweed, Hadley & McCloy LLP. Ms. Oien received a B.A. in Economics and Political Science from North Dakota State University and a J.D. from Loyola Law School.- Jessica Oien自2024年1月起担任Boundless Bio，Inc.首席法务官和公司秘书，并于2021年8月至2023年12月担任Boundless Bio，Inc.总法律顾问和公司秘书。在加入Boundless之前，Oien女士于2018年9月至2021年8月期间在上市的生物制药公司Cidara Therapeutics, Inc.担任总法律顾问和公司秘书。在加入Cidara之前，Oien女士曾在上市的生物制药公司Otonomy, Inc.担任法律与合规副总裁，2015年至2018年担任商业业务的法律主管，并带头推动商业合规计划。她曾担任Pernix Therapeutics法律与合规副总裁；Somaxon Pharmaceuticals法律事务与合规副总裁；Verus Pharmaceuticals法律事务高级总监，Elan Pharmaceuticals法律事务高级总监等类似职务。Oien女士的法律生涯始于Brobeck，Phleger & Harrison LLP和Milbank，Tweed，Hadley & McCloy LLP等国家律师事务所的公司法律顾问。Oien女士获得了北达科他州立大学经济学和政治学学士学位以及洛约拉法学院法学博士学位。
- Jessica Oien,has served as Boundless Bio, Inc. Chief Legal Officer and Corporate Secretary since January 2024 and as Boundless Bio, Inc. General Counsel and Corporate Secretary from August 2021 through December 2023. Prior to joining Boundless, Ms. Oien served as General Counsel and Corporate Secretary at Cidara Therapeutics, Inc., a publicly traded biopharmaceutical company, from September 2018 to August 2021. Before Cidara, Ms. Oien served as Vice President, Legal and Compliance at Otonomy, Inc., a publicly traded biopharmaceutical company, where she was the legal lead for the commercial business from 2015 to 2018 and spearheaded the commercial compliance program. She served in similar roles as Vice President, Legal and Compliance for Pernix Therapeutics; Vice President, Legal Affairs & Compliance for Somaxon Pharmaceuticals; and Senior Director, Legal Affairs for Verus Pharmaceuticals, and Senior Director, Legal Affairs at Elan Pharmaceuticals. Ms. Oien began her legal career as corporate counsel at national law firms including Brobeck, Phleger & Harrison LLP and Milbank, Tweed, Hadley & McCloy LLP. Ms. Oien received a B.A. in Economics and Political Science from North Dakota State University and a J.D. from Loyola Law School.